|
1
|
Siddik ZH: Cisplatin: mode of cytotoxic
action and molecular basis of resistance. Oncogene. 22:7265–7279.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kelland L: The resurgence of
platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584.
2007. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rabik CA and Dolan ME: Molecular
mechanisms of resistance and toxicity associated with platinating
agents. Cancer Treat Rev. 33:9–23. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Akervall J, Guo X, Qian CN, et al: Genetic
and expression profiles of squamous cell carcinoma of the head and
neck correlate with cisplatin sensitivity and resistance in cell
lines and patients. Clin Cancer Res. 10:8204–8213. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Tsunoda T, Koga H, Yokomizo A, et al:
Inositol 1, 4, 5-trisphosphate (IP3) receptor type1 (IP3R1)
modulates the acquisition of cisplatin resistance in bladder cancer
cell lines. Oncogene. 24:1396–1402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zeller C, Dai W, Steele NL, et al:
Candidate DNA methylation drivers of acquired cisplatin resistance
in ovarian cancer identified by methylome and expression profiling.
Oncogene. 31:4567–4576. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Zhang YW, Zheng Y, Wang JZ, et al:
Integrated analysis of DNA methylation and mRNA expression
profiling reveals candidate genes associated with cisplatin
resistance in non-small cell lung cancer. Epigenetics. 9:896–909.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Guo R, Wu G, Li H, et al: Promoter
methylation profiles between human lung adenocarcinoma multidrug
resistant A549/cisplatin (A549/DDP) cells and its progenitor A549
cells. Biol Pharm Bull. 36:1310–1316. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chang X, Monitto CL, Demokan S, et al:
Identification of hypermethylated genes associated with cisplatin
resistance in human cancers. Cancer Res. 70:2870–2879. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Batut P, Dobin A, Plessy C, Carninci P and
Gingeras TR: High-fidelity promoter profiling reveals widespread
alternative promoter usage and transposon-driven developmental gene
expression. Genome Res. 23:169–180. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Davuluri RV, Suzuki Y, Sugano S, Plass C
and Huang TH: The functional consequences of alternative promoter
use in mammalian genomes. Trends Genet. 24:167–177. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ayoubi TA and Van De Ven WJ: Regulation of
gene expression by alternative promoters. FASEB J. 10:453–460.
1996.PubMed/NCBI
|
|
13
|
Jacox E, Gotea V, Ovcharenko I and
Elnitski L: Tissue-specific and ubiquitous expression patterns from
alternative promoters of human genes. PLoS One. 5:e122742010.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Schibler U and Sierra F: Alternative
promoters in developmental gene expression. Annu Rev Genet.
21:237–257. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu H, Zhang Y, Li S, Yan Y and Li Y:
Dynamic regulation of glutamate decarboxylase 67 gene expression by
alternative promoters and splicing during rat testis maturation.
Mol Biol Rep. 37:3111–3119. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Xin D, Hu L and Kong X: Alternative
promoters influence alternative splicing at the genomic level. PLoS
One. 3:e23772008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Elso C, Lu X, Weisner PA, Thompson HL, et
al: A reciprocal translocation dissects roles of Pa×6 alternative
promoters and upstream regulatory elements in the development of
pancreas, brain, and eye. Genesis. 51:630–646. 2013.PubMed/NCBI
|
|
18
|
Smith RP, Lam ET, Markova S, Yee SW and
Ahituv N: Pharmacogene regulatory elements: from discovery to
applications. Genome Med. 4:452012. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Cusanovich DA, Pavlovic B, Pritchard JK
and Gilad Y: The functional consequences of variation in
transcription factor binding. PLoS Genet. 10:e10042262014.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang C, Bolotin E, Jiang T, Sladek FM and
Martinez E: Prevalence of the initiator over the TATA box in human
and yeast genes and identification of DNA motifs enriched in human
TATA-less core promoters. Gene. 389:52–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hsu PC, Chao CC, Yang CY, et al: Diverse
Hap43-independent functions of the Candida albicans CCAAT-binding
complex. Eukaryot Cell. 12:804–815. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gardiner-Garden M and Frommer M: CpG
islands in vertebrate genomes. J Mol Biol. 196:261–282. 1987.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Han L and Zhao Z: CpG islands or CpG
clusters: how to identify functional GC-rich regions in a genome?
BMC Bioinformatics. 10:652009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao Z and Han L: CpG islands: algorithms
and applications in methylation studies. Biochem Biophys Res
Commun. 382:643–645. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Hackenberg M, Barturen G, Carpena P,
Luque-Escamilla PL, Previti C and Oliver JL: Prediction of
CpG-island function: CpG clustering vs. sliding-window methods. BMC
Genomics. 11:3272010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
FANTOM Consortium the RIKEN PMI and CLST
(DGT)Forrest AR, Kawaji H, et al: A promoter-level mammalian
expression atlas. Nature. 507:462–470. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ben-Tabou de-Leon S and Davidson EH: Gene
regulation: gene control network in development. Annu Rev Biophys
Biomol Struct. 36:191–212. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jeziorska DM, Jordan KW and Vance KW: A
systems biology approach to understanding cis-regulatory module
function. Semin Cell Dev Biol. 20:856–862. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Cameron RA and Davidson EH: Flexibility of
transcription factor target site position in conserved
cis-regulatory modules. Dev Biol. 336:122–135. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Vavouri T and Elgar G: Prediction of
cis-regulatory elements using binding site matrices - the
successes, the failures and the reasons for both. Curr Opin Genet
Dev. 15:395–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Maston GA, Evans SK and Green MR:
Transcriptional regulatory elements in the human genome. Annu Rev
Genomics Hum Genet. 7:29–59. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Maston GA, Zhu LJ, Chamberlain L, Lin L,
Fang M and Green MR: Non-canonical TAF complexes regulate active
promoters in human embryonic stem cells. Elife. 1:e000682012.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Jaksik R and Rzeszowska-Wolny J: The
distribution of GC nucleotides and regulatory sequence motifs in
genes and their adjacent sequences. Gene. 492:375–381. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Martinez E: Core promoter-selective
coregulators of transcription by RNA polymerase II. Transcription.
3:295–299. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Gross P and Oelgeschläger T: Core
promoter-selective RNA polymerase II transcription. Biochem Soc
Symp. 73:225–236. 2006.PubMed/NCBI
|
|
36
|
Bucher P: Weight matrix descriptions of
four eukaryotic RNA polymerase II promoter elements derived from
502 unrelated promoter sequences. J Mol Biol. 212:563–578. 1990.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Camacho-Arroyo I, Hansberg-Pastor V and
Rodríguez-Dorantes M: DNA methylation analysis of steroid hormone
receptor genes. Methods Mol Biol. 1165:89–98. 2014.PubMed/NCBI
|
|
38
|
Cocozza S, Scala G, Miele G, Castaldo I
and Monticelli A: A distinct group of CpG islands shows
differential DNA methylation between replicas of the same cell line
in vitro. BMC Genomics. 14:6922013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Tanaka T, Bai T, Toujima S, et al:
Demethylation restores SN38 sensitivity in cells with acquired
resistance to SN38 derived from human cervical squamous cancer
cells. Oncol Rep. 27:1292–1298. 2012.PubMed/NCBI
|
|
40
|
Yang D and Okamoto K: Structural insights
into G-quadruplexes: towards new anticancer drugs. Future Med Chem.
2:619–646. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Chen Y and Yang D: Sequence, stability,
and structure of G-quadruplexes and their interactions with drugs.
Curr Protoc Nucleic Acid Chem. 17:Unit17.52012.PubMed/NCBI
|
|
42
|
Hudson JS, Brooks SC and Graves DE:
Interactions of actinomycin D with human telomeric G-quadruplex
DNA. Biochemistry. 48:4440–4447. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Meng H, Wang J, Xiong Z, Xu F, Zhao G and
Wang Y: Quantitative design of regulatory elements based on
high-precision strength prediction using artificial neural network.
PLoS One. 8:e602882013. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Brewster RC, Jones DL and Phillips R:
Tuning promoter strength through RNA polymerase binding site design
in Escherichia coli. PLoS Comput Biol. 8:e10028112012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Hosseinpour B, Bakhtiarizadeh MR, Khosravi
P and Ebrahimie E: Predicting distinct organization of
transcription factor binding sites on the promoter regions: a new
genome-based approach to expand human embryonic stem cell
regulatory network. Gene. 531:212–219. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Lai FJ, Chiu CC, Yang TH, Huang YM and Wu
WS: Identifying functional transcription factor binding sites in
yeast by considering their positional preference in the promoters.
PLoS One. 8:e837912013. View Article : Google Scholar : PubMed/NCBI
|
